Z
Zoran Erjavec
Publications - 5
Citations - 533
Zoran Erjavec is an academic researcher. The author has contributed to research in topics: Capecitabine & Bevacizumab. The author has an hindex of 5, co-authored 5 publications receiving 460 citations.
Papers
More filters
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).
Miriam Koopman,Lieke H.J. Simkens,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E. de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jacobus J. M. van der Hoeven,Peter Nieboer,Jürgen Braun,Rob L. H. Jansen,Janny G. Haasjes,Annemieke Cats,J. Wals,Linda Mol,Otilia Dalesio,Harm van Tinteren,Cornelis J. A. Punt +19 more
TL;DR: The CAIRO3 study investigated the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation in mCRC pts not progressing during induction treatment withCAPOX-B.
Journal ArticleDOI
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Geke A. P. Hospers,Michael Schaapveld,J.W.R. Nortier,J.A. Wils,A. van Bochove,R. S. de Jong,G. J. Creemers,Zoran Erjavec,D. J. de Gooyer,P. H. Th. J. Slee,C. J. H. Gerrits,J. M. Smit,Nanno Mulder +12 more
TL;DR: Oxaliplatin in the first-line with bolus FU/LV in metastatic colorectal cancer resulted in an increased RR and PFS with less grade 3/4 mucositis/diarrhoea compared with 5FU/LV alone and despite a low treatment cross over rate, OS in both groups was comparable.
Journal ArticleDOI
Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel
Carolien P. Schröder,Linda de Munck,Anneke M. Westermann,Willem M. Smit,Geert-Jan Creemers,Hiltje de Graaf,Jacqueline M. Stouthard,Gert A. van Deijk,Zoran Erjavec,Aart van Bochove,Willemijn Vader,Pax H.B. Willemse +11 more
TL;DR: In this article, the authors compared weekly single-agent docetaxel with 3-week single agent (3-week) and 3-weekly single agent(3-month) with a multicenter, randomised, open-label phase III trial.
Journal ArticleDOI
Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.
Judith R. Kroep,Erik van Werkhoven,Marco B. Polee,Cees J. van Groeningen,Aart Beeker,Frans L. G. Erdkamp,N.I. Weijl,Aart van Bochove,Zoran Erjavec,Ellen Kapiteijn,Anne M. Stiggelbout,Hans W. R. Nortier,Hans Gelderblom +12 more
TL;DR: UFT/leucovorin and capecitabine had similar efficacy and different toxicity profiles in frail elderly patients with aCRC.